(Reuters) — Northfield Laboratories Inc. said U.S. regulators have granted a priority review for the company's experimental treatment for the loss of red blood cell, sending its shares to a new-year high. Shares of the company more than doubled to $1.31 in morning trade on Nasdaq, up 77 ...
